Zydus Cadila gets USFDA nod for multiple sclerosis drug Fingolimod
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis.
Ahmedabad: Pharma major, Zydus Cadila, has recently announced that the company has received tentative approval from the United States Food & Drug Administration (USFDA) to market Fingolimod Capsules in the strength of .25 mg (US RLD: Gilenya Capsules).
Earlier, in October 2020, the group was granted approval to market Fingolimod Capsules in the strength of .5mg.
Fingolimod is an immunomodulating drug.
It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila may seek DCGI nod for ZyCoV-D next week: Report
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.